Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 393

  • The following term was not found in PubMed: TA-7284[ti].
1.

Two Glucose-Lowering Mechanisms of Canagliflozin Depending on Body Weight Changes in Drug-Naïve Subjects with Type 2 Diabetes.

Kutoh E, Wada A, Murayama T, Hayashi J.

Drugs R D. 2018 Oct 15. doi: 10.1007/s40268-018-0250-z. [Epub ahead of print]

PMID:
30324549
2.

Canagliflozin-loaded magnetic nanoparticles as potential treatment of hypoxic tumors in combination with radiotherapy.

Angelopoulou A, Kolokithas-Ntoukas A, Papaioannou L, Kakazanis Z, Khoury N, Zoumpourlis V, Papatheodorou S, Kardamakis D, Bakandritsos A, Hatziantoniou S, Avgoustakis K.

Nanomedicine (Lond). 2018 Oct 12. doi: 10.2217/nnm-2018-0145. [Epub ahead of print]

PMID:
30311542
3.

Effect of Canagliflozin on Heart Function Involving Ketone Bodies in Patients with Type 2 Diabetes.

Kutoh E, Hayashi J.

Drug Res (Stuttg). 2018 Oct 8. doi: 10.1055/a-0748-5745. [Epub ahead of print]

PMID:
30296805
4.

Effect of canagliflozin on nocturnal home blood pressure in Japanese patients with type 2 diabetes mellitus: The SHIFT-J study.

Kario K, Hoshide S, Okawara Y, Tomitani N, Yamauchi K, Ohbayashi H, Itabashi N, Matsumoto Y, Kanegae H.

J Clin Hypertens (Greenwich). 2018 Oct;20(10):1527-1535. doi: 10.1111/jch.13367. Epub 2018 Sep 23.

5.

Metabolic Acidosis in Postsurgical Patient on Canagliflozin and Metformin: A Case Report.

Darwish AM.

A A Pract. 2018 Sep 18. doi: 10.1213/XAA.0000000000000888. [Epub ahead of print]

PMID:
30234515
6.

Effect of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on cisplatin-induced nephrotoxicity in mice.

Abdelrahman AM, Al Suleimani Y, Shalaby A, Ashique M, Manoj P, Nemmar A, Ali BH.

Naunyn Schmiedebergs Arch Pharmacol. 2018 Sep 11. doi: 10.1007/s00210-018-1564-7. [Epub ahead of print]

PMID:
30206656
7.

The combination of canagliflozin and omega-3 fatty acid ameliorates insulin resistance and cardiac biomarkers via modulation of inflammatory cytokines in type 2 diabetic rats.

Safhi MM, Anwer T, Khan G, Siddiqui R, Moni Sivakumar S, Alam MF.

Korean J Physiol Pharmacol. 2018 Sep;22(5):493-501. doi: 10.4196/kjpp.2018.22.5.493. Epub 2018 Aug 27.

8.

Mechanistic insights from sequential combination therapy with a sodium glucose co-transporter-2 inhibitor and a dipeptidyl peptidase-4 inhibitor: Results from the CANARIS Trial using canagliflozin and teneligliptin.

Okahata S, Sakamoto K, Mitsumatsu T, Kondo Y, Tanaka S, Shiba T.

Diabetes Obes Metab. 2018 Aug 26. doi: 10.1111/dom.13505. [Epub ahead of print]

PMID:
30146790
10.

Euglycaemic diabetic ketoacidosis in bariatric surgery patients with type 2 diabetes taking canagliflozin.

van Niekerk C, Wallace J, Takata M, Yu R.

BMJ Case Rep. 2018 Aug 20;2018. pii: bcr-2017-221527. doi: 10.1136/bcr-2017-221527.

PMID:
30131409
11.

Diabetic patients with essential hypertension treated with amlodipine: blood pressure and arterial stiffness effects of canagliflozin or perindopril.

Ramirez AJ, Sanchez MJ, Sanchez RA.

J Hypertens. 2018 Aug 14. doi: 10.1097/HJH.0000000000001907. [Epub ahead of print]

PMID:
30113526
12.

Effect of Canagliflozin on Urinary Albumin Excretion in Japanese Patients with Type 2 Diabetes Mellitus and Microalbuminuria: A Pilot Study.

Osonoi T, Gouda M, Kubo M, Arakawa K, Hashimoto T, Abe M.

Diabetes Technol Ther. 2018 Oct;20(10):681-688. doi: 10.1089/dia.2018.0169. Epub 2018 Aug 10.

13.
14.

Canagliflozin Improves the Recovery of Blood Flow in an Experimental Model of Severe Limb Ischemia.

Sherman SE, Bell GI, Teoh H, Al-Omran M, Connelly KA, Bhatt DL, Hess DA, Verma S.

JACC Basic Transl Sci. 2018 May 30;3(2):327-329. doi: 10.1016/j.jacbts.2018.01.010. eCollection 2018 Apr. No abstract available.

15.

Canagliflozin attenuates the progression of atherosclerosis and inflammation process in APOE knockout mice.

Nasiri-Ansari Ν, Dimitriadis GK, Agrogiannis G, Perrea D, Kostakis ID, Kaltsas G, Papavassiliou AG, Randeva HS, Kassi E.

Cardiovasc Diabetol. 2018 Jul 26;17(1):106. doi: 10.1186/s12933-018-0749-1.

16.

Canagliflozin.

Drugs and Lactation Database (LactMed) [Internet]. Bethesda (MD): National Library of Medicine (US); 2006-.

17.

Cardiovascular and Renal Outcomes With Canagliflozin According to Baseline Kidney Function: Data from the CANVAS Program.

Neuen BL, Ohkuma T, Neal B, Matthews DR, de Zeeuw D, Mahaffey KW, Fulcher G, Desai M, Li Q, Deng H, Rosenthal N, Jardine MJ, Bakris G, Perkovic V.

Circulation. 2018 Jun 25. pii: CIRCULATIONAHA.118.035901. doi: 10.1161/CIRCULATIONAHA.118.035901. [Epub ahead of print]

PMID:
29941478
18.

Comparative effectiveness of canagliflozin, SGLT2 inhibitors and non-SGLT2 inhibitors on the risk of hospitalization for heart failure and amputation in patients with type 2 diabetes mellitus: A real-world meta-analysis of 4 observational databases (OBSERVE-4D).

Ryan PB, Buse JB, Schuemie MJ, DeFalco F, Yuan Z, Stang PE, Berlin JA, Rosenthal N.

Diabetes Obes Metab. 2018 Nov;20(11):2585-2597. doi: 10.1111/dom.13424. Epub 2018 Jun 25.

PMID:
29938883
19.

Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials.

Perkovic V, de Zeeuw D, Mahaffey KW, Fulcher G, Erondu N, Shaw W, Barrett TD, Weidner-Wells M, Deng H, Matthews DR, Neal B.

Lancet Diabetes Endocrinol. 2018 Sep;6(9):691-704. doi: 10.1016/S2213-8587(18)30141-4. Epub 2018 Jun 21.

PMID:
29937267
20.

Effects of Canagliflozin on Fatty Liver Indexes in Patients with Type 2 Diabetes: A Meta-analysis of Randomized Controlled Trials.

Li B, Wang Y, Ye Z, Yang H, Cui X, Wang Z, Liu L.

J Pharm Pharm Sci. 2018;21(1):222-235. doi: 10.18433/jpps29831.

Supplemental Content

Loading ...
Support Center